



18 November 2021

ASX ANNOUNCEMENT

Share Purchase Plan Successfully Completed

ImpediMed Limited (**ImpediMed** or the **Company**) (ASX:IPD) is pleased to announce the successful completion of its Share Purchase Plan (**SPP**). The SPP closed on Thursday, 12 November 2021 heavily oversubscribed, with more than 1,500 applications received for a total of over \$32 million, well in excess of the Company's target of \$5 million.

The SPP was announced on 27 October 2021 following the completion of a \$35 million placement (**Placement**). The SPP was offered to eligible shareholders to raise up to \$5 million with each eligible shareholder allowed to subscribe for up to \$30,000 of new ordinary shares in the Company at a price of \$0.1525, equivalent to the issue price under the Placement, subject to any scale back.

Consistent with the strong interest in the recent Placement, there was also very strong demand for shares offered under the SPP, with over \$32 million in demand. In accordance with the terms and conditions of the SPP, and to accommodate a more equitable resolution, the Company has enacted the following:

- The SPP was increased to \$7.5 million.
- In the case of shareholders with minimal holdings, often a solitary share, where a pro rata allocation would result in a nominal amount, the Company has used its discretion and rejected these applications.
- All remaining applications will receive a minimum SPP application amount of \$1,000 (i.e., 6,558 shares at an issue price of \$0.1525): and
- After the distribution of the minimum amount, the remaining SPP application amount has been allocated on a proportional basis, based on the size of the applicant's shareholding at the record date.

In total 49,180,077 new fully paid shares will be issued under the SPP. The SPP Shares are expected to be issued on Thursday, 18 November 2021 and to commence trading on the ASX on Friday, 19 November 2021. Holding statements are expected to be dispatched to successful applicants on Thursday, 18 November 2021. Excess application monies will be refunded to applicants shortly, as detailed in the SPP Offer Booklet.

"We would like to thank all shareholders who applied to participate in the SPP and are appreciative of the support it shows in our collective vision. We are now in a fully funded position to execute on the Oncology opportunity post PREVENT, while still investing in our other key focus areas of Renal Failure and Heart Failure," commented Richard Carreon, Managing Director and CEO of ImpediMed.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO Digital Health Platform

SOZO, the world's most advanced, non-invasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphoedema, provides fluid status for patients living with heart or renal failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.